OXFORD BIOMEDICA - Key Persons
Job Titles:
- Independent Non - Executive Director
Job Titles:
- Independent Non - Executive Director
- Professor Dame Kay Davies
Dr. Heather Preston was appointed to Oxford Biomedica ™s Board as a Non-Executive Director in March 2018 and was appointed Chair of the Remuneration Committee in June 2020. Dr. Preston is a Partner and Managing Director of TPG Biotech. She has over 25 years of experience in healthcare, as a scientist, physician and management consultant and she has been an investor in life sciences and biotechnology for the last 19 years. Dr. Preston holds a degree in Medicine from the University of Oxford.
Dr. Hayden was appointed as a Non-Executive Director of Oxford Biomedica in July 2021. He was previously the President of Global R&D and Chief Scientific Officer at Teva Pharmaceuticals Industries Ltd. and has co-founded five biotechnology companies: Prilenia Therapeutics B.V., NeuroVir Therapeutics Inc., Xenon Pharmaceuticals Inc., Aspreva Pharmaceuticals Corp and 89bio, Inc. He currently serves as CEO of Prilenia Therapeutics and represents various biotech companies at Board level.
Dr. Rao joined Oxford Biomedica in March 2022 as Chief Medical Officer. He will be dividing his time between his role at Oxford Biomedica with roles at SV Health Investors and Sitryx. Dr. Rao brings long standing bio pharmaceutical and translation experience from early stage through to launch and life cycle across multiple therapeutic areas with different treatment modalities. Most recently, Dr. Rao was Head of R&D and Chief Medical Officer at Swedish Orphan Biovitrum (Sobi), where he oversaw the development and approval of multiple medicines in rare diseases across immunology and haematology.
Dr. Roch Doliveux was appointed to Oxford Biomedica ™s Board as Non-Executive Chair in June 2020. Dr. Doliveux also became Interim CEO in January 2022. He is currently Chair of the Board of Directors at Pierre Fabre S.A..Dr. Doliveux was previously the Chief Executive Officer of UCB S.A. for ten years during which time he transformed the company from a diversified chemical group into a global biopharmaceutical leader. Prior to this Dr. Doliveux worked at Schering-Plough International, Inc. from 1990 "2003 and at Ciba-Geigy AG (now Novartis) from 1982-1990. Dr. Doliveux is a Veterinary Surgeon by training and has an MBA from INSEAD.
Job Titles:
- Independent Non - Executive Director
Dr. Siyamak ( œSam ) Rasty was appointed to Oxford Biomedica ™s Board as a Non-Executive Director in December 2020. Dr. Rasty is currently the President and Chief Executive Officer of PlateletBio, a US-based pioneering cell-based therapeutics company. Previously, he served as Chief Operating Officer at Homology Medicines, Inc., a genetic medicines company that he helped launch in 2016 and transform into an established, fully integrated public gene therapy and gene editing company. Prior to joining Homology, he held senior positions at Shire Pharmaceuticals, Endo Pharmaceuticals, and at GlaxoSmithKline. Dr. Rasty holds a Ph.D. in Biochemistry from Louisiana State University, where he focused on transcriptional regulation of lentiviruses, completed a postdoctoral fellowship at the University of Pittsburgh School of Medicine, and received an MBA from Villanova University.
Dr. Miskin joined Oxford Biomedica in 2000. He has more than 18 years ™ experience in cell and gene therapy, 14 of which have been in the GxP (good practice) environment. In his current role, he has overall responsibility for Oxford Biomedica ™s Quality systems, analytical testing and lentiviral based bioprocessing development, as well as client programmes and alliance management. He is also a named inventor on several patents in the field. He holds a Bachelor of Science degree and a PhD in Molecular Biology from the University of Leeds and subsequently conducted post-doctoral research at The Pirbright Institute for a number of years. He is a member of the UK BioIndustry Association Manufacturing Advisory Committee and is the Advanced Therapies workstream lead for The Medicines Manufacturing Industry Partnership (MMIP).
Job Titles:
- Chief Business and Corporate Development Officer
- in 2015 As Head of Business Development
Dr. Slingsby joined Oxford Biomedica in 2015 as Head of Business Development and was promoted to Chief Business and Corporate Development Officer in May 2019. He has 20 years ™ experience in the biotechnology industry in biologics, vaccines and gene therapy. He has worked in international business development roles at Sosei Co., Ltd. and Intercell AG and was cofounder and CEO of ProtAffin AG, a venture capital backed company in Austria and UK. Jason started his career as a post-doctoral scientist at Oxford Biomedica and first worked at the company 1997 "2000. He was awarded a 1st class BA (Hons) in Biochemistry from Magdalen College, Oxford University and also completed a PhD in complex disease genetics from Imperial College London. Jason was also awarded an MBA with distinction from London Business School in 2002.
Dr. Mitrophanous joined Oxford Biomedica in 1997. He has over 20 years of lentiviral vector experience covering a range of technical disciplines, including the development of cell and gene therapies, delivery platform technologies, bioprocessing and analytics. He is a recognised world-class expert in the field, a named inventor on numerous lentiviral vector patents and an author of a number of key papers. In his current role, he is responsible for the development of Oxford Biomedica ™s new product candidates and LentiVector ® platform. He holds a PhD in Molecular Biology from University College London and has conducted post-doctoral research at the University of Oxford.
Job Titles:
- Chief People Officer
- Senior Executive
Lisa James joined Oxford Biomedica ™s Senior Executive Team in April 2022, having worked with the company since 2016. Lisa joined Oxford Biomedica as HR Manager and during her six-year tenure has been promoted to Head of HR Delivery and Head of HR Business Partnering and Development. Previously Lisa worked as HR Manager for a European third-party High-Tech Logistics organisation, specialising in medical devices. Lisa has over 13 years ™ experience in Human Resources and a CIPD Level 7 Advanced Diploma in Human Resource Management.
Job Titles:
- Chief Information Officer
- Senior Executive
Matthew Treagus joined Oxford Biomedica ™s Senior Executive Team in August 2021 as Chief Information Officer, having worked as a consultant with the company since 2019. He has over 30 years ™ experience of applying technology to support growth, innovation and efficiency.
Matthew was a co-founder of AKQA, a digital services business now part of WPP Group plc, a pioneer of the internet services industry. Most recently, he was a Partner at Baringa Partners LLP with responsibilities in the Customer and Digital team working across the Retail, Financial Services and Energy sectors.
Matthew ran his own consultancy business for twelve years advising a diverse set of clients, including Oxford Biomedica. He has also served as Interim CIO at Save the Children UK.
Job Titles:
- Independent Non - Executive Director
Namrata P Patel was appointed to Oxford Biomedica ™s Board as an Independent Non-Executive Director in April 2022. Ms Patel has extensive international experience in manufacturing and end to end Supply Chain ‹management, ‹as well as experience in the commercialised regulated industry. She has held ‹positions of increasing seniority in major blue chip companies including Coca Cola , W H Smith Office Supplies, Gillette, and currently leads the Global Beauty Sector Supply Chain in Procter & Gamble, playing a key role in delivering their 2040 Sustainability Ambition Goals. She holds a Masters in Logistics and Management from the Cranfield School of Management, and a BA Hons in Public Administration from the University of South Wales, Mid Glamorgan.
Job Titles:
- General Counsel
- Company Secretary and Registered Office
Natalie Walter joined Oxford Biomedica in May 2019 as General Counsel. She has over 20 years ™ experience as a corporate lawyer advising life sciences companies, including Oxford Biomedica, on a range of business and transactional issues, equity capital markets transactions, mergers and acquisitions and Corporate Governance. Natalie also sits on the Board of C4X Discovery Holdings plc as a Non-Executive Director. Natalie has worked for a number of UK and US law firms, as well as working at Lehman Brothers as a Director and Legal Counsel for the Equity Capital Markets division. She was most recently a Partner with Covington & Burling LLP.
Nick Page joined Oxford Biomedica in April 2019. Prior to joining he held a number of senior operational leadership positions in the pharmaceutical industry, most recently as Platform Head of Anti-infectives within Novartis. His 40+ years of industry experience include API, Solid oral dose, Sterile, and Radiopharmaceutical manufacturing in various organisations encompassing innovative, generic and contract manufacturing. During his career he has spent several years working in China and India as well as in Global roles. He originally qualified as a Chartered Chemist and also has an MBA from The Open University
Robert Ghenchev was appointed to Oxford Biomedica ™s Board as a Non-Executive Director in June 2019. Robert is currently Head of Growth Equity at Novo Holdings. Prior to joining Novo Holdings, he was an investment banker at Moelis & Company and Deutsche Bank in London. Mr Ghenchev has deep corporate finance experience advising life science companies on a wide range of issues. He holds a J.Hons. B.A. degree in Finance and Economics from McGill University and a M.Sc. degree in Financial Economics from the University of Oxford.
Job Titles:
- Deputy Chair
- Senior Independent Non - Executive Director
Stuart Henderson was appointed to Oxford Biomedica ™s Board as a Non-Executive Director and Chair of the Audit Committee in June 2016. He became Deputy Chair and Senior Independent Director in June 2020. Previously, Mr Henderson was a partner at Deloitte, where he was Head of European Healthcare and Life Sciences. Prior to this he was a Partner at Arthur Andersen. Mr Henderson has extensive audit and transaction experience and has worked with life sciences businesses for 35 years. Mr Henderson is a former Director of the Babraham Institute and Norwich Research Partners LLP and a Non-Executive Director at OneNucleus (the Life Sciences trade body for Cambridge and London), Biocity Group Limited and Cell Therapy Catapult Limited.
Stuart Paynter joined Oxford Biomedica and the Board in August 2017. Mr Paynter has 17 years ™ experience in the pharmaceutical and healthcare sectors. He qualified as a chartered accountant with Haines Watts before moving to EDS. He subsequently joined Steris, and worked in a variety of roles within the healthcare and life sciences divisions prior to becoming the European Finance Director. Mr Paynter moved to Shire Pharmaceuticals where he became the Senior Director of Finance Business Partnering for all business outside of the US. He then moved to a corporate finance role before becoming the Global Head of Internal Audit. Prior to joining Oxford Biomedica Mr Paynter was Head of Finance Business Partnering at De La Rue plc. He is a member of the Institute of Chartered Accountants in England and Wales.
Job Titles:
- Chief Executive Officer of Oxford Biomedica Solutions
Tim Kelly joined Oxford Biomedica as Chief Executive Officer of Oxford Biomedica Solutions and Chair of its Board of Directors in March 2022. Mr Kelly has over 20 years ™ experience in global product development and manufacturing which he gained whilst working for a range of pharmaceutical companies in Europe and the USA. Prior to joining Oxford Biomedica PLC, Mr Kelly was Chief Operating Officer at Homology Medicines Inc. Mr Kelly has an MBA from Troy University as well as a BSc in Engineering Mechanics from the United States Air Force Academy.